Target Discovery

Discover and evaluate novel targets for your disease of interest by the unique combination of Euretos computational disease models and direct access to the Euretos AI Platform.

 

Increase target discovery potential and success

We work closely with many pharmaceutical & biotech companies to identify and evaluate more potentially valuable therapeutic targets. We help them take a biomolecular data-driven approach and empower their domain experts with the tools to evaluate novel targets more effectively and quickly.

Ranked target predictions from AI-powered computational disease models
Biomolecular data-driven approach that maximises discovery potential
Your domain experts assess results using the Euretos AI Platform
Comprehensive 360 degree, rapid target evaluation capabilities
Euretos
Target Discovery

Data-driven, novel target candidates

Euretos computational disease models predict novel target-indication combinations by assessing whether a target’s biological interactors are linked to known disease associations. These ranked target predictions can then be reviewed independently by our client's domain experts using the Euretos AI Platform.

SCIENTISTcomlogo     We support purchasing via scientist.com and science exchange!     Science_Exchange_logo

 

Euretos
Target Discovery

Maximise target discovery potential 

To find truly novel targets, we focus on biomolecular and experimental data to minimise literature bias. Discovery potential is further increased by taking into account the indications associated with a target’s biological interaction networks. This way many yet unexplored targets are considered.
Euretos
Target Discovery

Empower your domain experts to evaluate target predictions

We provide our clients domain experts access to the Euretos AI Platform to evaluate the predicted targets. Here they can assess key target and disease aspects such as multi-omics interactions, gene expression in tissues, cell types and tumors, pathway interactions, regulatory and signalling responses, gene variants, clinical trials, target tractability and patents.

360 degree biological, functional and commercial target assessment

As part of the Euretos AI platform, researchers will have access to the Target Assessment workflow with relevant expression data (tissue, cell type, tumor, cell line), functional annotations, pathway analysis, drug candidates, patents, clinical trials and more! Much of this data is difficult to find or integrated manually by Euretos. This enables a rapid and comprehensive assessment of target potential within a specific disease or phenotypical context.
Enabling world leading pharma, biotech and academic institutions
Genmab
Janssen and Janssen Pharmaceutical Companies
Leiden Academic Centre for Drug Research
Astra Zeneca
Boehringer Ingelheim
Tufts University
Euretos
Target Discovery

A collaborative research approach

Combine your proprietary data and therapeutic expertise with our computational disease models, translational consultants and AI platform to gain collaborative, data-driven disease insights.
Enabling world leading pharma, biotech and academic institutions
janssen-logo-05F09E3DB9-seeklogo.com
Logo Daiichi Sankyo
Logo EMC-1
Lundbeck_Euretos
Logo Sanofi-1
Logo LUMC-1

Transforming Disease and Drug Research

Get started Free access for academic users!
Request a Demo